Piper Jaffray Cuts Price Target on Jazz Pharmaceuticals (JAZZ) to $178 Following Mixed 2Q
Piper Jaffray maintained an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $178.00 (from $188.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)